Rezurock (belumosudil tablets - Kadmon) — Cigna

Initial criteria

• Patient age ≥ 12 years
• Patient has chronic graft-versus-host disease
• Patient has tried at least two systemic medications for chronic graft-versus-host disease

Reauthorization criteria

• According to the prescriber, the patient demonstrates a beneficial clinical response (e.g., reduction in corticosteroid dose, disease stabilization, and/or symptomatic improvement)

Approval duration

1 year